According to Zhitong Finance APP, Yidu Technology (02158) rose more than 16%, as of press time, rising 16.16% to 5.68 Hong Kong dollars, with a transaction volume of 0.152 billion Hong Kong dollars.

On the news front, on November 23, the National Medical Insurance Administration held a press conference to interpret the 17 batches of pricing projects. The National Medical Insurance Administration stated that in order to support relatively mature ai-assisted technologies entering clinical applications while preventing additional burden on patients, it analyzed potential application scenarios of ai in radiation examinations, ultrasonic examinations, and rehabilitation projects, establishing 'ai-assisted' expansion items, which means that at the same price level, hospitals can choose to train medical personnel for diagnosis and treatment, or they can choose to use ai in diagnostic and treatment activities, but currently, no duplicate charges are incurred.

The company recently released its mid-term performance for the 2025 fiscal year, achieving total revenue of 0.329 billion yuan. During this period, the loss was reduced to 56.36 million yuan, a year-on-year reduction of 29.2%, and cash flow continued to optimize and improve. As a leading domestic ai medical industry player, Yidu Technology continuously invested in ai technology during the reporting period, particularly in the research and commercialization of self-developed medical vertical large language models, and promoted ai's application in specific scenarios. Everbright Securities pointed out that considering the empowerment of the ai medical smart brain YiduCore in delivering full-scene solutions, the adjusted EBITDA maintained profitability, and the 'buy' rating was upheld.